These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32468178)

  • 1. Reply to the letter by Gaetano Loscocco, Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.
    Takami A
    Int J Hematol; 2020 Jul; 112(1):127. PubMed ID: 32468178
    [No Abstract]   [Full Text] [Related]  

  • 2. Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.
    Loscocco GG
    Int J Hematol; 2020 Jul; 112(1):125-126. PubMed ID: 32474804
    [No Abstract]   [Full Text] [Related]  

  • 3. Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.
    Takami A
    Int J Hematol; 2020 Jul; 112(1):122-124. PubMed ID: 32399895
    [No Abstract]   [Full Text] [Related]  

  • 4. Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients.
    M MB; L B; I A; P D; E I; F C; M LV; J M; M FR; M U; G H
    J Infect; 2020 Sep; 81(3):452-482. PubMed ID: 32579985
    [No Abstract]   [Full Text] [Related]  

  • 5. Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis.
    Dimopoulos G; de Mast Q; Markou N; Theodorakopoulou M; Komnos A; Mouktaroudi M; Netea MG; Spyridopoulos T; Verheggen RJ; Hoogerwerf J; Lachana A; van de Veerdonk FL; Giamarellos-Bourboulis EJ
    Cell Host Microbe; 2020 Jul; 28(1):117-123.e1. PubMed ID: 32411313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etoposide-based therapy for severe forms of COVID-19.
    Hamizi K; Aouidane S; Belaaloui G
    Med Hypotheses; 2020 Sep; 142():109826. PubMed ID: 32416415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
    Miao Y; Fan L; Li JY
    Front Immunol; 2020; 11():1445. PubMed ID: 32612616
    [No Abstract]   [Full Text] [Related]  

  • 8. Haemophagocytic lymphohistiocytosis in COVID-19 cases?
    Tveiten H; Aukrust P; Lehne G; Rodriguez JR; Skjønsberg OH
    Tidsskr Nor Laegeforen; 2020 Apr; 140(6):. PubMed ID: 32321221
    [No Abstract]   [Full Text] [Related]  

  • 9. Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19.
    Faguer S; Del Bello A; Abravanel F; Nicolau-Travers ML; Kamar N
    Ann Intern Med; 2020 Sep; 173(6):501-503. PubMed ID: 32432518
    [No Abstract]   [Full Text] [Related]  

  • 10. Hemophagocytic syndrome: a potential COVID-19 complication.
    Amaral LTW; Fonseca EKUN; Jacomelli M; Szarf G; Chate RC
    J Bras Pneumol; 2020 Sep; 46(5):e20200296. PubMed ID: 32965311
    [No Abstract]   [Full Text] [Related]  

  • 11. Haemophagocytosis in bone marrow aspirates in patients with COVID-19.
    Debliquis A; Harzallah I; Mootien JY; Poidevin A; Labro G; Mejri A; Lamarque M; Kuteifan K; Drénou B
    Br J Haematol; 2020 Jul; 190(2):e70-e73. PubMed ID: 32529634
    [No Abstract]   [Full Text] [Related]  

  • 12. Tremor and ataxia in COVID-19.
    Diezma-Martín AM; Morales-Casado MI; García-Alvarado N; Vadillo Bermejo A; López-Ariztegui N; Sepúlveda Berrocal MA
    Neurologia (Engl Ed); 2020; 35(6):409-410. PubMed ID: 32571554
    [No Abstract]   [Full Text] [Related]  

  • 13. The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVID-19.
    Loscocco GG; Malandrino D; Barchiesi S; Berni A; Poggesi L; Guglielmelli P; Vannucchi AM
    Int J Lab Hematol; 2020 Dec; 42(6):e270-e273. PubMed ID: 32776691
    [No Abstract]   [Full Text] [Related]  

  • 14. [Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].
    Hasselbalch HC; Poulsen A; Skov V; Kjær L; Nielsen CH; Poulsen TD
    Ugeskr Laeger; 2020 Jun; 182(25):. PubMed ID: 32584762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 Associated Hemophagocytic Lymphohistiocytosis and Coagulopathy: Targeting the Duumvirate.
    Bhattacharjee S; Banerjee M; Pal R
    Indian Pediatr; 2020 Sep; 57(9):827-833. PubMed ID: 32583809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemophagocytic lymphohistiocytosis in SARS-CoV-2 infection.
    Dewaele K; Claeys R
    Blood; 2020 Jun; 135(25):2323. PubMed ID: 32556137
    [No Abstract]   [Full Text] [Related]  

  • 17. Secondary HLH is uncommon in severe COVID-19.
    Wood H; Jones JR; Hui K; Mare T; Pirani T; Galloway J; Metaxa V; Benjamin R; Rutherford A; Cain S; Kulasekararaj AG
    Br J Haematol; 2020 Sep; 190(5):e283-e285. PubMed ID: 32526046
    [No Abstract]   [Full Text] [Related]  

  • 18. Opioid Use Disorder Treatment and Potential Interactions With Novel COVID-19 Medications: A Clinical Perspective.
    Mansuri Z; Shah B; Trivedi C; Beg U; Patel H; Jolly T
    Prim Care Companion CNS Disord; 2020 Jul; 22(4):. PubMed ID: 32628368
    [No Abstract]   [Full Text] [Related]  

  • 19. The Possible Protective Role of α-Synuclein Against Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Patients With Parkinson's Disease.
    Ait Wahmane S; Achbani A; Ouhaz Z; Elatiqi M; Belmouden A; Nejmeddine M
    Mov Disord; 2020 Aug; 35(8):1293-1294. PubMed ID: 32519352
    [No Abstract]   [Full Text] [Related]  

  • 20. Outcome of Parkinson's Disease Patients Affected by COVID-19.
    Antonini A; Leta V; Teo J; Chaudhuri KR
    Mov Disord; 2020 Jun; 35(6):905-908. PubMed ID: 32347572
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.